TRACON Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Key information
6.5%
Earnings growth rate
57.2%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 77.8% |
Return on equity | n/a |
Net Margin | -29.8% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Tracon Pharmaceuticals announces $35M non-dilutive debt facility
Sep 06Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma
Aug 29Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M
Aug 10TRACON Pharmaceuticals announces $5M registered direct offering
Dec 29TRACON Pharma launches $8.8M direct offering
Dec 22Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study
Dec 10Tracon Pharma files China application for envafolimab in solid tumors
Nov 16Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow TRACON Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 12 | -4 | 7 | 0 |
30 Sep 23 | 9 | -11 | 7 | 0 |
30 Jun 23 | 9 | -28 | 8 | 2 |
31 Mar 23 | 0 | -28 | 10 | 0 |
31 Dec 22 | 0 | -29 | 14 | 0 |
30 Sep 22 | 0 | -30 | 17 | 0 |
30 Jun 22 | 0 | -30 | 19 | 6 |
31 Mar 22 | 0 | -33 | 21 | 0 |
31 Dec 21 | 0 | -29 | 18 | 0 |
30 Sep 21 | 0 | -25 | 15 | 0 |
30 Jun 21 | 0 | -22 | 13 | 0 |
31 Mar 21 | 0 | -18 | 9 | 0 |
31 Dec 20 | 0 | -17 | 8 | 0 |
30 Sep 20 | 0 | -16 | 8 | 0 |
30 Jun 20 | 0 | -18 | 8 | -3 |
31 Mar 20 | 0 | -19 | 8 | 0 |
31 Dec 19 | 0 | -23 | 8 | 0 |
30 Sep 19 | 0 | -26 | 8 | -5 |
30 Jun 19 | 0 | -30 | 8 | 0 |
31 Mar 19 | 0 | -34 | 7 | -2 |
31 Dec 18 | 3 | -35 | 7 | 0 |
30 Sep 18 | 3 | -34 | 7 | 7 |
30 Jun 18 | 10 | -24 | 7 | 6 |
31 Mar 18 | 11 | -20 | 7 | 6 |
31 Dec 17 | 9 | -19 | 8 | 0 |
30 Sep 17 | 9 | -19 | 8 | 7 |
30 Jun 17 | 3 | -26 | 8 | 7 |
31 Mar 17 | 3 | -28 | 8 | 7 |
31 Dec 16 | 3 | -27 | 8 | 6 |
30 Sep 16 | 4 | -32 | 8 | 6 |
30 Jun 16 | 5 | -32 | 7 | 6 |
31 Mar 16 | 8 | -27 | 7 | 6 |
31 Dec 15 | 8 | -24 | 6 | 5 |
30 Sep 15 | 8 | -16 | 5 | 4 |
30 Jun 15 | 8 | -12 | 4 | 4 |
31 Mar 15 | 4 | -10 | 3 | 3 |
31 Dec 14 | 4 | -7 | 2 | 3 |
30 Sep 14 | 3 | -7 | 2 | 2 |
30 Jun 14 | 1 | -7 | 2 | 2 |
31 Mar 14 | 0 | -8 | 2 | 2 |
Growing Profit Margin: TCON is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TCON is unprofitable, but has reduced losses over the past 5 years at a rate of 6.5% per year.